超重影响了通过肝功能障碍在日本风湿性关节炎患者中升级最佳的甲二甲剂量和效果
Soshi Takahashi1,2, Miho Shibata1, Miho Takahashi1
1The Shinko Institute for Medical Research, Shinko Hospital, Kobe, Japan.
International journal of rheumatic diseases
|November 21, 2025
概括
超重的类风湿性关节炎 (RA) 患者对甲状腺素 (MTX) 的反应减少. 超重个体肝酶升高可能会限制MTX的剂量,影响治疗的有效性.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
背景情况:
- 类风湿性关节炎 (RA) 管理通常涉及甲状腺素 (MTX).
- 超重状态可以影响药物的有效性和安全性.
- 在日本RA患者中,超重对MTX的影响需要进一步调查.
研究的目的:
- 评估超重如何影响日本RA患者的MTX疗效和肝功能.
- 确定肝功能障碍是否有助于在超重的RA患者中限制MTX剂量和治疗耐药性.
主要方法:
- 71名日本RA患者开始MTX的回顾性队列研究.
- 患者分为正常体重 (<25.0 kg/m2) 和超重 (≥25.0 kg/m2) 的两组.
- 在48周内评估了DAS28-CRP,肝酶和MTX剂量.
主要成果:
- 超重的RA患者表现出MTX疗效显著降低 (24周和48周的较小 ΔDAS28-CRP).
- 超重个体每体重MTX剂量较低,肝酶 (AST,ALT,γ-GTP) 升高,表明剂量限制性肝功能障碍.
- 在超重患者中脂肪肝的更高患病率与较差的MTX反应相关.
结论:
- 超重与日本RA患者的MTX反应减弱有关.
- 肝酶升高和随后的MTX剂量限制可能解释了超重的RA患者的疗效降低.
- 建议对超重的RA患者进行体重管理和生活方式干预,以改善治疗结果.
相关概念视频
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
01:21Drug Dosing: Obese Patients
204
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
204
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
162
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
162
01:29Therapeutic Drug Monitoring: Affecting Factors
183
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
183
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170